Logo image of VIVO

MERIDIAN BIOSCIENCE INC (VIVO) Stock Fundamental Analysis

NASDAQ:VIVO - Nasdaq - US5895841014 - Common Stock - Currency: USD

33.97  0 (0%)

After market: 33.99 +0.02 (+0.06%)

Fundamental Rating

6

Taking everything into account, VIVO scores 6 out of 10 in our fundamental rating. VIVO was compared to 187 industry peers in the Health Care Equipment & Supplies industry. Both the health and profitability get an excellent rating, making VIVO a very profitable company, without any liquidiy or solvency issues. VIVO has a valuation in line with the averages, but on the other hand it scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

8

1. Profitability

1.1 Basic Checks

In the past year VIVO was profitable.
In the past year VIVO had a positive cash flow from operations.
Each year in the past 5 years VIVO has been profitable.
Each year in the past 5 years VIVO had a positive operating cash flow.
VIVO Yearly Net Income VS EBIT VS OCF VS FCFVIVO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 20M 40M 60M 80M 100M

1.2 Ratios

The Return On Assets of VIVO (9.17%) is better than 88.89% of its industry peers.
With an excellent Return On Equity value of 11.54%, VIVO belongs to the best of the industry, outperforming 87.50% of the companies in the same industry.
With an excellent Return On Invested Capital value of 14.66%, VIVO belongs to the best of the industry, outperforming 94.44% of the companies in the same industry.
The Average Return On Invested Capital over the past 3 years for VIVO is significantly above the industry average of 7.92%.
The 3 year average ROIC (49.65%) for VIVO is well above the current ROIC(14.66%). The reason for the recent decline needs to be investigated.
Industry RankSector Rank
ROA 9.17%
ROE 11.54%
ROIC 14.66%
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)49.65%
ROIC(5y)N/A
VIVO Yearly ROA, ROE, ROICVIVO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 5 10 15 20 25

1.3 Margins

Looking at the Profit Margin, with a value of 12.75%, VIVO belongs to the top of the industry, outperforming 87.04% of the companies in the same industry.
VIVO's Profit Margin has improved in the last couple of years.
With an excellent Operating Margin value of 22.70%, VIVO belongs to the best of the industry, outperforming 93.52% of the companies in the same industry.
VIVO's Operating Margin has been stable in the last couple of years.
VIVO has a Gross Margin (56.56%) which is in line with its industry peers.
VIVO's Gross Margin has declined in the last couple of years.
Industry RankSector Rank
OM 22.7%
PM (TTM) 12.75%
GM 56.56%
OM growth 3Y5.46%
OM growth 5Y0.35%
PM growth 3Y1.65%
PM growth 5Y3.46%
GM growth 3Y-1.43%
GM growth 5Y-1.79%
VIVO Yearly Profit, Operating, Gross MarginsVIVO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 20 40 60

More info and screens

8

2. Health

2.1 Basic Checks

With a Return on Invested Capital (ROIC) well above the Cost of Capital (WACC), VIVO is creating value.
VIVO has more shares outstanding than it did 1 year ago.
The debt/assets ratio for VIVO has been reduced compared to a year ago.
VIVO Yearly Shares OutstandingVIVO Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 10M 20M 30M 40M
VIVO Yearly Total Debt VS Total AssetsVIVO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 100M 200M 300M 400M

2.2 Solvency

VIVO has an Altman-Z score of 11.77. This indicates that VIVO is financially healthy and has little risk of bankruptcy at the moment.
With an excellent Altman-Z score value of 11.77, VIVO belongs to the best of the industry, outperforming 88.89% of the companies in the same industry.
The Debt to FCF ratio of VIVO is 0.34, which is an excellent value as it means it would take VIVO, only 0.34 years of fcf income to pay off all of its debts.
The Debt to FCF ratio of VIVO (0.34) is better than 93.52% of its industry peers.
A Debt/Equity ratio of 0.07 indicates that VIVO is not too dependend on debt financing.
With a Debt to Equity ratio value of 0.07, VIVO perfoms like the industry average, outperforming 56.94% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.07
Debt/FCF 0.34
Altman-Z 11.77
ROIC/WACC1.53
WACC9.57%
VIVO Yearly LT Debt VS Equity VS FCFVIVO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 100M 200M 300M

2.3 Liquidity

VIVO has a Current Ratio of 3.63. This indicates that VIVO is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 3.63, VIVO is in line with its industry, outperforming 50.00% of the companies in the same industry.
A Quick Ratio of 2.46 indicates that VIVO has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 2.46, VIVO is in line with its industry, outperforming 45.83% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 3.63
Quick Ratio 2.46
VIVO Yearly Current Assets VS Current LiabilitesVIVO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 50M 100M 150M 200M

More info and screens

3

3. Growth

3.1 Past

VIVO shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -17.86%.
The Earnings Per Share has been growing by 15.21% on average over the past years. This is quite good.
The Revenue has been growing slightly by 4.76% in the past year.
Measured over the past years, VIVO shows a quite strong growth in Revenue. The Revenue has been growing by 10.65% on average per year.
EPS 1Y (TTM)-17.86%
EPS 3Y26.61%
EPS 5Y15.21%
EPS Q2Q%-12.5%
Revenue 1Y (TTM)4.76%
Revenue growth 3Y18.33%
Revenue growth 5Y10.65%
Sales Q2Q%-13.82%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-39.02%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year-13.66%
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
VIVO Yearly Revenue VS EstimatesVIVO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 100M 200M 300M
VIVO Yearly EPS VS EstimatesVIVO Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 0.5 1 1.5

More info and screens

5

4. Valuation

4.1 Price/Earnings Ratio

A Price/Earnings ratio of 24.62 indicates a rather expensive valuation of VIVO.
Compared to the rest of the industry, the Price/Earnings ratio of VIVO indicates a rather cheap valuation: VIVO is cheaper than 83.80% of the companies listed in the same industry.
When comparing the Price/Earnings ratio of VIVO to the average of the S&P500 Index (26.82), we can say VIVO is valued inline with the index average.
With a Price/Forward Earnings ratio of 40.37, VIVO can be considered very expensive at the moment.
Based on the Price/Forward Earnings ratio, VIVO is valued a bit cheaper than the industry average as 75.93% of the companies are valued more expensively.
VIVO's Price/Forward Earnings ratio indicates a similar valuation than the S&P500 average which is at 36.21.
Industry RankSector Rank
PE 24.62
Fwd PE 40.37
VIVO Price Earnings VS Forward Price EarningsVIVO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60

4.2 Price Multiples

Based on the Enterprise Value to EBITDA ratio, VIVO is valued cheaper than 86.57% of the companies in the same industry.
VIVO's Price/Free Cash Flow ratio is rather cheap when compared to the industry. VIVO is cheaper than 94.44% of the companies in the same industry.
Industry RankSector Rank
P/FCF 20.27
EV/EBITDA 15.62
VIVO Per share dataVIVO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 2 4 6 8

4.3 Compensation for Growth

The excellent profitability rating of VIVO may justify a higher PE ratio.
PEG (NY)N/A
PEG (5Y)1.62
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

VIVO does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

MERIDIAN BIOSCIENCE INC

NASDAQ:VIVO (1/30/2023, 8:27:46 PM)

After market: 33.99 +0.02 (+0.06%)

33.97

0 (0%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)01-26 2023-01-26/amc
Earnings (Next)05-04 2023-05-04/amc
Inst Owners0%
Inst Owner Change0%
Ins Owners2.73%
Ins Owner Change0%
Market Cap1.49B
Analysts43.33
Price Target34.68 (2.09%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)17.65%
Min EPS beat(2)-1.96%
Max EPS beat(2)37.25%
EPS beat(4)3
Avg EPS beat(4)27.19%
Min EPS beat(4)-1.96%
Max EPS beat(4)37.25%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-2.54%
Min Revenue beat(2)-4.52%
Max Revenue beat(2)-0.56%
Revenue beat(4)2
Avg Revenue beat(4)6.92%
Min Revenue beat(4)-4.52%
Max Revenue beat(4)23.21%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)-4.62%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)-5.21%
Valuation
Industry RankSector Rank
PE 24.62
Fwd PE 40.37
P/S 4.49
P/FCF 20.27
P/OCF 18.15
P/B 4.06
P/tB 8.42
EV/EBITDA 15.62
EPS(TTM)1.38
EY4.06%
EPS(NY)0.84
Fwd EY2.48%
FCF(TTM)1.68
FCFY4.93%
OCF(TTM)1.87
OCFY5.51%
SpS7.57
BVpS8.36
TBVpS4.04
PEG (NY)N/A
PEG (5Y)1.62
Profitability
Industry RankSector Rank
ROA 9.17%
ROE 11.54%
ROCE N/A
ROIC 14.66%
ROICexc 18.35%
ROICexgc 44.57%
OM 22.7%
PM (TTM) 12.75%
GM 56.56%
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)49.65%
ROIC(5y)N/A
ROICexc(3y)19.62%
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3Y10.61%
ROICexcg growth 5Y2.24%
ROICexc growth 3Y13.29%
ROICexc growth 5Y-2.41%
OM growth 3Y5.46%
OM growth 5Y0.35%
PM growth 3Y1.65%
PM growth 5Y3.46%
GM growth 3Y-1.43%
GM growth 5Y-1.79%
F-Score5
Asset Turnover0.72
Health
Industry RankSector Rank
Debt/Equity 0.07
Debt/FCF 0.34
Debt/EBITDA 0.27
Cap/Depr 52.18%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality 173.69%
Current Ratio 3.63
Quick Ratio 2.46
Altman-Z 11.77
F-Score5
WACC9.57%
ROIC/WACC1.53
Cap/Depr(3y)65.44%
Cap/Depr(5y)57.5%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)112.8%
Profit Quality(5y)119.92%
High Growth Momentum
Growth
EPS 1Y (TTM)-17.86%
EPS 3Y26.61%
EPS 5Y15.21%
EPS Q2Q%-12.5%
EPS Next Y-39.02%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)4.76%
Revenue growth 3Y18.33%
Revenue growth 5Y10.65%
Sales Q2Q%-13.82%
Revenue Next Year-13.66%
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-25.75%
EBIT growth 3Y24.79%
EBIT growth 5Y11.03%
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y51.89%
FCF growth 3Y31.57%
FCF growth 5Y14.86%
OCF growth 1Y23.18%
OCF growth 3Y31.55%
OCF growth 5Y14.77%